title: Uveitis-like syndrome and iris transillumination after the use of oral moxifloxacin.
authors.forename: F
authors.initials: F
authors.lastname: Willermain
authors.forename: C
authors.initials: C
authors.lastname: Deflorenne
authors.forename: C
authors.initials: C
authors.lastname: Bouffioux
authors.forename: X
authors.initials: X
authors.lastname: Janssens
authors.forename: P
authors.initials: P
authors.lastname: Koch
authors.forename: L
authors.initials: L
authors.lastname: Caspers
mesh_terms: D000328:Adult; D000890:Anti-Infective Agents / Q000009:adverse effects*; D001372:Aza Compounds / Q000009:adverse effects*; D005128:Eye Diseases / Q000473:pathology; D024841:Fluoroquinolones; D006801:Humans; D007429:Intraocular Pressure; D007498:Iris / Q000473:pathology* / Q000601:surgery; D017075:Laser Coagulation; D008297:Male; D000077266:Moxifloxacin; D010859:Pigmentation Disorders / Q000473:pathology; D011804:Quinolines / Q000009:adverse effects*; D014172:Transillumination; D016896:Treatment Outcome; D014606:Uveitis, Anterior / Q000139:chemically induced* / Q000473:pathology*
chemical_list: D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin